INEX Innovate

INEX Innovate INEX INNOVATE is Asia’s women's focused life-sciences group, providing precision health care for women, specifically for Asian phenotypes.

INEX has a broad commercial portfolio of validated tests in prenatal health, ovarian and breast cancers. INEX Innovate - Asia's women's life sciences innovation group. Spun out from the National University of Singapore (NUS), INEX Innovate is a Singapore based molecular diagnostics developer and medical laboratory operator. Founded by veteran maternal foetal medicine specialists, INEX is uniquely

positioned to identify and address clinically unmet needs within the women’s and foetal health landscape. INEX focuses on developing and translating technologies that aim to deliver precision health healthcare for women in Asia. We have a broad commercial portfolio of validated tests and 48 key patents, including;

· An Ovarian Cancer Cyst test that determines if an ovarian cyst is benign
or malignant.
· A liquid biopsy based Breast Cancer test.
· A liquid biopsy based Ovarian Cancer early detection test
· Non Invasive Pre Natal Test (NIPT)
· Non Invasive Pre Natal Diagnostic (NIPD)


Through our wholly owned subsidiary iGene Laboratory Pte Ltd, INEX operates a state of the art Next Generation Sequencing Laboratory that provides diagnostic testing, clinical research (CRO) and COVID-19 testing services. In 2020, INEX was a finalist in the Business Transformation of the Year award category at the British Chamber of Commerce Singapore Annual Business Awards in recognition of its efforts in launching new technologies and pivoting towards COVID-19 testing to support Singapore’s battle against the coronavirus pandemic. The company also received the Frost & Sullivan ‘Singapore Clinical Laboratories in Women’s Health Entrepreneurial Company of the Year Award’ in 2021 and was also recognized by World Intellectual Property Organization (WIPO) and the Intellectual Property Office of Singapore (IPOS) with the 2021 IP for Innovation Champion Award. For more information visit: www.inex.sg

29/01/2024
𝐓𝐡𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐓𝐢𝐦𝐞𝐬 feature on INEX Innovate - chronicling our incredible journey and remarkable growth in the realms of ...
17/01/2024

𝐓𝐡𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐓𝐢𝐦𝐞𝐬 feature on INEX Innovate - chronicling our incredible journey and remarkable growth in the realms of “chromosomes, cancer, and COVID”, as part of the Enterprise 50 Awards 📈🧬

This series is part of the Enterprise 50 Educational project with the NUS Business School, National University of Singapore.

The annual E50 Rankings is co-organised by The Business Times and KPMG, sponsored by OCBC Bank and supported by Enterprise Singapore, SGX Group and Singapore Business Federation.

Luxury lifestyle, news and business publication - LUXUO chronicles INEX Innovate's ascent in the world of women’s and fe...
10/01/2024

Luxury lifestyle, news and business publication - LUXUO chronicles INEX Innovate's ascent in the world of women’s and fetal maternal health in a wide ranging interview with INEX Chief Executive Kane Black where they discuss INEX’s role on the future of fetal-maternal care and oncology alongside INEX’s ambition to “democratise diagnostics” and Kane’s journey through the medtech industry.

https://www.luxuo.com/business/inex-chief-executive-kane-black-on-innovating-the-future-of-medtech.html

LUXUO speaks to the man making waves in medical research and innovations in the MedTech sector alongside the growth of INEX.

Address

1 Science Park Road, #04-10 The Capricorn
Singapore
117528

Website

Alerts

Be the first to know and let us send you an email when INEX Innovate posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to INEX Innovate:

Shortcuts

Share

Category

Our Story

ABOUT US

The Company focuses on Innovations in Molecular Diagnostics— ideating, developing and translating new technologies to address unmet needs in women’s and fetal health. The Company’s vision is to make its technologies accessible to women across Asia and around the world, and to give women and mothers greater certainty and confidence in diagnostic testing by pushing the boundaries of science.

INEX currently has in excess of forty-seven key patents, nine trademarks, and exclusive licences for Next Generation Sequencing Technology and Non Invasive Prenatal Testing from Global Centres of Medical Excellence. The Company is backed by institutional and government shareholders including Enterprise Singapore, Genting Berhad, Zicom MedTacc and PriceWaterhouseCoopers.

For more information please visit; http://www.inex.sg